GlobalData on MSN6h
Eli Lilly reports outcomes from Phase III trial of tirzepatide for HFpEF
The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.
Yahoo Finance25m
Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure
On Saturday, Eli Lilly And Co (NYSE:LLY) released detailed results from the SUMMIT Phase 3 trial showing tirzepatide reduced ...
Eli Lilly’s tirzepatide cuts risk of worsening heart failure in HFpEF, obese patients
Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...
News Medical on MSN2h
Tirzepatide improves heart health and function in obese HFpEF patients
In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...
pharmaphorum4h
Tirzepatide gets a big win in obesity-related heart failure
"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...
Eyenovia stock plummets following Phase III myopia trial failure
The failure of Eyenovia's CHAPERONE study has seen the company’s stock value drop drastically as it considers options and ...
Organic carrots recalled over E- Coli outbreak
An E. coli outbreak that has sickened dozens of people and caused one death is tied to bagged, organic baby carrots sold ...
pharmaphorum15h
AI could 'cut ECG result wait times and speed up treatment'
The trial of the PanEcho software, presented at the American Heart Association (AHA) congress in Chicago, suggests that it ...